Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. 2005 Feb; 64(2): 267–272.
PMCID: PMC1755343

Gout epidemiology: results from the UK General Practice Research Database, 1990–1999


Objective: To examine the epidemiology of gout and gout treatment in the United Kingdom using a large national practice based population.

Methods: Data from the UK General Practice Research Database from 1990 to 1999 were examined. Physician diagnoses and drug codes were used, and trends in gout incidence and treatment examined. Additionally, disease prevalence for the year 1999 was assessed. To examine the association of gout with comorbid disease, the prevalence of select health conditions and drug use was compared with the corresponding prevalences seen in osteoarthritis, adjusting for both age and sex.

Results: From 1 January 1990 to 31 December 1999 overall gout incidence remained relatively stable, ranging from a low of 11.9 cases (95% confidence interval (CI) 11.5 to 12.3) in 1991 to a high of 18.0 cases (95% CI 17.6 to 18.4) per 10 000 patient-years in 1994. Gout prevalence in 1999 was 1.4% with rates approaching 7% in men over the age of 65. Drugs used for the treatment of gout remained constant in prevalent cases with the exception of a significant decline in non-steroidal anti-inflammatory drug use over the 10 year follow up. Compared with patients with osteoarthritis, patients with gout were significantly more likely to have cardiovascular disease, hypertension, diabetes, and chronic renal failure, and were more likely to have used diuretics or ciclosporin, or both.

Conclusion: Although gout is common in the UK, particularly among older men, the incidence of the disease seems to have remained stable during the 1990s.

Full Text

The Full Text of this article is available as a PDF (197K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Arromdee Emvalee, Michet Clement J, Crowson Cynthia S, O'Fallon W Michael, Gabriel Sherine E. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002 Nov;29(11):2403–2406. [PubMed]
  • Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis. 1997 Jan;56(1):22–26. [PMC free article] [PubMed]
  • Currie WJ. Prevalence and incidence of the diagnosis of gout in Great Britain. Ann Rheum Dis. 1979 Apr;38(2):101–106. [PMC free article] [PubMed]
  • Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol. 1995 Sep;48(9):1153–1158. [PubMed]
  • Hollowell J. The General Practice Research Database: quality of morbidity data. Popul Trends. 1997 Spring;(87):36–40. [PubMed]
  • García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998 May;45(5):419–425. [PMC free article] [PubMed]
  • Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991 Mar 30;302(6779):766–768. [PMC free article] [PubMed]
  • Lewis James D, Brensinger Colleen, Bilker Warren B, Strom Brian L. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf. 2002 Apr-May;11(3):211–218. [PubMed]
  • Stewart OJ, Silman AJ. Review of UK data on the rheumatic diseases--4. Gout. Br J Rheumatol. 1990 Dec;29(6):485–488. [PubMed]
  • Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med. 1967 Jan;42(1):27–37. [PubMed]
  • Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987 Mar;82(3):421–426. [PubMed]
  • Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol. 1988;41(3):237–242. [PubMed]
  • Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ. Racial differences in the incidence of gout. The role of hypertension. Arthritis Rheum. 1995 May;38(5):628–632. [PubMed]
  • Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. JAMA. 1991 Dec 4;266(21):3004–3007. [PubMed]
  • Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977 Apr;20(3):895–900. [PubMed]
  • Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1995 Apr 1;141(7):637–644. [PubMed]
  • Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000 May 10;283(18):2404–2410. [PubMed]
  • Grodzicki T, Palmer A, Bulpitt CJ. Incidence of diabetes and gout in hypertensive patients during 8 years of follow-up. The General Practice Hypertension Study Group. J Hum Hypertens. 1997 Sep;11(9):583–585. [PubMed]
  • Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000 Jun;27(6):1501–1505. [PubMed]
  • Haffner Steven M. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract. 2003 Jul;61 (Suppl 1):S9–S18. [PubMed]
  • Halabe A, Sperling O. Uric acid nephrolithiasis. Miner Electrolyte Metab. 1994;20(6):424–431. [PubMed]
  • Kramer Holly J, Choi Hyon K, Atkinson Karen, Stampfer Meir, Curhan Gary C. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int. 2003 Sep;64(3):1022–1026. [PubMed]
  • Kramer Holly Mattix, Curhan Gary. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis. 2002 Jul;40(1):37–42. [PubMed]
  • Chin MH, Wang LC, Jin L, Mulliken R, Walter J, Hayley DC, Karrison TG, Nerney MP, Miller A, Friedmann PD. Appropriateness of medication selection for older persons in an urban academic emergency department. Acad Emerg Med. 1999 Dec;6(12):1232–1242. [PubMed]

Figures and Tables

Figure 1
 (A) Overall and sex-specific annual gout incidence (1990–99) among enrolees in the UK GPRD. (B) Annual UK gout incidence (1990–99) by age distribution. 95% CIs (shown with bars) calculated using normal approximation.
Figure 2
 Gout prevalence (1999) among enrolees in the UK GPRD. 95% CIs (shown with bars) calculated using normal approximation.
Figure 3
 Annual frequency of NSAID, allopurinol, and glucocorticoid use among prevalent patients with gout (n = 63 105) enrolled in the UK GPRD, 1990–1999; frequency of use includes any prescription received within the same calendar year. Colchicine ...

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...